[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100549641":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":76,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":85,"sex":90,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":96,"studyType":97,"phases":10,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Peking University First Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prospective study group",null,"The group included patients with confirmed cutaneous T-cell lymphoma (CTCL) based on clinical features and histopathology from three research units: Peking University First Hospital, Peking University Third Hospital, and Beijing Institute of Cancer Prevention and Treatment. According to the immunohistochemistry algorithm established previously, the formalin-fixed and paraffin-embedded skin lesions of the patients will be stained. Patients will be assigned to different molecular subtypes, and the treatment strategy will be selected based on the classification.",[13],"Other: molecular subtype based treatment",{"label":15,"type":10,"description":16,"interventionNames":10},"Retrospective control group","The control group included patients with complete baseline information and previous follow-up data in the TACTICAL database, established by Peking University First Hospital in 2009 for cutaneous lymphoma cases.",[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"molecular subtype based treatment","The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.",[9],[23],{"name":24,"affiliation":5,"role":25},"YANG WANG, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Yang Wang, MD","CONTACT","86-10-83572350","yangwang_dr@bjmu.edu.cn",[33,56,66],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Beijing","Beijing Municipality","100034","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47,49,53,54],{"name":48,"role":29,"phone":30,"phoneExt":10,"email":31},"YANG ZHANG, MD",{"name":50,"role":29,"phone":51,"phoneExt":10,"email":52},"ZHUOJING CHEN, MD","86+01083572350","chenzhuojing15@gmail.com",{"name":24,"role":25,"phone":10,"phoneExt":10,"email":10},{"name":50,"role":55,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"facility":57,"status":34,"city":35,"state":36,"zip":58,"country":38,"countryCode":39,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Beijing Cancer Hospital","100142",{"type":41,"coordinates":60},[43,44],{"lat":44,"lon":43},[63],{"name":64,"role":29,"phone":10,"phoneExt":10,"email":65},"WENQING LI, MD","pan-kf@263.net",{"facility":67,"status":34,"city":35,"state":36,"zip":68,"country":38,"countryCode":39,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"Peking University Third Hospital","100191",{"type":41,"coordinates":70},[43,44],{"lat":44,"lon":43},[73],{"name":74,"role":29,"phone":10,"phoneExt":10,"email":75},"CHUNLEI ZHANG, MD","zhangchunleius@163.com",{"type":25,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yang WANG","The Chief of Department of Dermatology and Venereology",[80,81],{"name":67,"class":6},{"name":82,"class":6},"Peking University Cancer Hospital & Institute","100549641","a-study-of-molecular-subtyping-based-therapeutic-strategies-for-cutaneous-t-cell-lymphoma-100549641",false,"NCT06436677","A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma","AMITY","Inclusion Criteria:\n\n* Signed informed consent;\n* Patients with CTCL who do not respond well to targeted skin therapy (topical corticosteroids, nitrogen mustard, or phototherapy) in the early stage (stage I-IIA) and advanced stage (stage IIB-IV);\n* Age 18-75 years;\n* Expected survival time greater than 3 months (follow-up for the historical control group was greater than 3 months);\n\nExclusion Criteria:\n\n* Received other anti-tumor therapy other than skin-targeted therapy (phototherapy, topical hormones or nitrogen mustard) within the past 1 month prior to enrollment;\n* Patients with 2 or more types of primary cutaneous T-cell lymphoma at the same time;\n* Combined with other malignant tumors, still receiving anti-tumor therapy;\n* Has any other active disease that may increase the risk of protocol therapy or impair the patient\\'s ability to receive protocol therapy, including but not limited to:\n\n  * Comorbid epilepsy;\n  * Comorbid autoimmune diseases;\n  * Combined with hepatic decompensation;\n  * Patients with renal insufficiency and creatinine clearance \\< 50ml\u002Fmin;\n* Have an uncontrollable medical condition, including but not limited to:\n\n  * Ongoing or active infection;\n  * Clinically significant healing or non-healing wounds;\n  * Symptomatic congestive heart failure, unstable angina, clinically significant arrhythmias;\n  * Significant lung disease (e.g., shortness of breath at rest or light activity, or need for supplemental oxygen for any reason);\n  * Diseases\u002Fconditions that affect study compliance, such as infectious diseases or psychiatric illnesses\u002Fsocial situations, that are uncontrollable;\n* Pregnant (or intending to become pregnant within 2 years) or lactating females;\n* Concomitant participation in interventional clinical trials of other clinical trial drugs, except for questionnaire surveys or observational studies;\n* Any situation in which the programme is not in compliance;\n* Other conditions that in the opinion of the investigator are not suitable for participation in this study.","ALL","18 Years","75 Years",{"count":94,"type":95},100,"ESTIMATED","2 Years","OBSERVATIONAL","Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden.",[100,101],"Cutaneous T-Cell Lymphoma\u002FMycosis Fungoides","Cutaneous T Cell Lymphoma",[103,104,105],"cutaneous T-cell lymphoma","mycosis fungoides","Sezary syndrome","2024-05-24",{"date":108,"type":109},"2024-05-31","ACTUAL",{"date":111,"type":109},"2024-05-09",{"date":113,"type":95},"2030-12-31",{"name":5,"class":6},3]